Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypomanic and depressive symptoms

Aymery Constant, Laurent Castera, Robert Dantzer, Patrice Couzigou, Victor De Ledinghen, Jacques Demotes-Mainard, Chantal Henry

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Background: Psychiatric side effects are common during interferon-alfa (IFN-alfa) therapy and often responsible for early treatment discontinuation, thus limiting its therapeutic potential. Depression is considered the hallmark of these side effects. However, irritability, anger/hostility, and manic/hypomanic episodes have also been reported, suggesting that these symptoms are important features of IFN-alfa-induced neuropsychiatric side effects. Objective: The aim of this prospective study was to use item-by-item analysis to thoroughly characterize neuropsychiatric symptoms occurring during early IFN-alfa therapy in a large cohort of patients with chronic hepatitis C. Method: Ninety-three previously IFN-alfa-naive patients treated with pegylated IFN-alfa plus ribavirin for chronic hepatitis C were studied. Neuropsychiatric assessments were conducted before initiation and after weeks 4 and 12 of antiviral therapy. They included the Mini-International Neuropsychiatric Interview, the 10-item Montgomery-Asberg Depression Rating Scale, the State-Trait Anxiety Inventory, and the Brief Fatigue Inventory. Results: Psychiatric events occurred in 30 patients (32%). They consisted of mood disorders in all cases: mania in 3 cases (10%), irritable hypomania in 15 cases (50%), and depressive mixed states in 12 cases (40%). Neurovegetative symptoms appeared within 4 weeks in most patients. In patients who developed mood disorders, sadness and depressive thoughts were present but minimal in severity. In contrast, inner tension and anxiety symptoms increased significantly over time only in these patients. Conclusions: Our results suggest that IFN-alfa-induced mood disorders are common and consist of an overlap between depressive and manic symptoms rather than a mere depression. The impact of such findings on therapeutic management should be investigated.

Original languageEnglish (US)
Pages (from-to)1050-1057
Number of pages8
JournalJournal of Clinical Psychiatry
Volume66
Issue number8
DOIs
StatePublished - Aug 2005

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Depression
Mood Disorders
Psychiatry
Therapeutics
Anxiety
Equipment and Supplies
Hostility
Ribavirin
Anger
Bipolar Disorder
Antiviral Agents
Fatigue
Prospective Studies
Interviews

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C : Evidence for an overlap between manic/hypomanic and depressive symptoms. / Constant, Aymery; Castera, Laurent; Dantzer, Robert; Couzigou, Patrice; De Ledinghen, Victor; Demotes-Mainard, Jacques; Henry, Chantal.

In: Journal of Clinical Psychiatry, Vol. 66, No. 8, 08.2005, p. 1050-1057.

Research output: Contribution to journalArticle

Constant, Aymery ; Castera, Laurent ; Dantzer, Robert ; Couzigou, Patrice ; De Ledinghen, Victor ; Demotes-Mainard, Jacques ; Henry, Chantal. / Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C : Evidence for an overlap between manic/hypomanic and depressive symptoms. In: Journal of Clinical Psychiatry. 2005 ; Vol. 66, No. 8. pp. 1050-1057.
@article{e40bb6ff94094d21a826065bf35080e7,
title = "Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypomanic and depressive symptoms",
abstract = "Background: Psychiatric side effects are common during interferon-alfa (IFN-alfa) therapy and often responsible for early treatment discontinuation, thus limiting its therapeutic potential. Depression is considered the hallmark of these side effects. However, irritability, anger/hostility, and manic/hypomanic episodes have also been reported, suggesting that these symptoms are important features of IFN-alfa-induced neuropsychiatric side effects. Objective: The aim of this prospective study was to use item-by-item analysis to thoroughly characterize neuropsychiatric symptoms occurring during early IFN-alfa therapy in a large cohort of patients with chronic hepatitis C. Method: Ninety-three previously IFN-alfa-naive patients treated with pegylated IFN-alfa plus ribavirin for chronic hepatitis C were studied. Neuropsychiatric assessments were conducted before initiation and after weeks 4 and 12 of antiviral therapy. They included the Mini-International Neuropsychiatric Interview, the 10-item Montgomery-Asberg Depression Rating Scale, the State-Trait Anxiety Inventory, and the Brief Fatigue Inventory. Results: Psychiatric events occurred in 30 patients (32{\%}). They consisted of mood disorders in all cases: mania in 3 cases (10{\%}), irritable hypomania in 15 cases (50{\%}), and depressive mixed states in 12 cases (40{\%}). Neurovegetative symptoms appeared within 4 weeks in most patients. In patients who developed mood disorders, sadness and depressive thoughts were present but minimal in severity. In contrast, inner tension and anxiety symptoms increased significantly over time only in these patients. Conclusions: Our results suggest that IFN-alfa-induced mood disorders are common and consist of an overlap between depressive and manic symptoms rather than a mere depression. The impact of such findings on therapeutic management should be investigated.",
author = "Aymery Constant and Laurent Castera and Robert Dantzer and Patrice Couzigou and {De Ledinghen}, Victor and Jacques Demotes-Mainard and Chantal Henry",
year = "2005",
month = "8",
doi = "10.4088/JCP.v66n0814",
language = "English (US)",
volume = "66",
pages = "1050--1057",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C

T2 - Evidence for an overlap between manic/hypomanic and depressive symptoms

AU - Constant, Aymery

AU - Castera, Laurent

AU - Dantzer, Robert

AU - Couzigou, Patrice

AU - De Ledinghen, Victor

AU - Demotes-Mainard, Jacques

AU - Henry, Chantal

PY - 2005/8

Y1 - 2005/8

N2 - Background: Psychiatric side effects are common during interferon-alfa (IFN-alfa) therapy and often responsible for early treatment discontinuation, thus limiting its therapeutic potential. Depression is considered the hallmark of these side effects. However, irritability, anger/hostility, and manic/hypomanic episodes have also been reported, suggesting that these symptoms are important features of IFN-alfa-induced neuropsychiatric side effects. Objective: The aim of this prospective study was to use item-by-item analysis to thoroughly characterize neuropsychiatric symptoms occurring during early IFN-alfa therapy in a large cohort of patients with chronic hepatitis C. Method: Ninety-three previously IFN-alfa-naive patients treated with pegylated IFN-alfa plus ribavirin for chronic hepatitis C were studied. Neuropsychiatric assessments were conducted before initiation and after weeks 4 and 12 of antiviral therapy. They included the Mini-International Neuropsychiatric Interview, the 10-item Montgomery-Asberg Depression Rating Scale, the State-Trait Anxiety Inventory, and the Brief Fatigue Inventory. Results: Psychiatric events occurred in 30 patients (32%). They consisted of mood disorders in all cases: mania in 3 cases (10%), irritable hypomania in 15 cases (50%), and depressive mixed states in 12 cases (40%). Neurovegetative symptoms appeared within 4 weeks in most patients. In patients who developed mood disorders, sadness and depressive thoughts were present but minimal in severity. In contrast, inner tension and anxiety symptoms increased significantly over time only in these patients. Conclusions: Our results suggest that IFN-alfa-induced mood disorders are common and consist of an overlap between depressive and manic symptoms rather than a mere depression. The impact of such findings on therapeutic management should be investigated.

AB - Background: Psychiatric side effects are common during interferon-alfa (IFN-alfa) therapy and often responsible for early treatment discontinuation, thus limiting its therapeutic potential. Depression is considered the hallmark of these side effects. However, irritability, anger/hostility, and manic/hypomanic episodes have also been reported, suggesting that these symptoms are important features of IFN-alfa-induced neuropsychiatric side effects. Objective: The aim of this prospective study was to use item-by-item analysis to thoroughly characterize neuropsychiatric symptoms occurring during early IFN-alfa therapy in a large cohort of patients with chronic hepatitis C. Method: Ninety-three previously IFN-alfa-naive patients treated with pegylated IFN-alfa plus ribavirin for chronic hepatitis C were studied. Neuropsychiatric assessments were conducted before initiation and after weeks 4 and 12 of antiviral therapy. They included the Mini-International Neuropsychiatric Interview, the 10-item Montgomery-Asberg Depression Rating Scale, the State-Trait Anxiety Inventory, and the Brief Fatigue Inventory. Results: Psychiatric events occurred in 30 patients (32%). They consisted of mood disorders in all cases: mania in 3 cases (10%), irritable hypomania in 15 cases (50%), and depressive mixed states in 12 cases (40%). Neurovegetative symptoms appeared within 4 weeks in most patients. In patients who developed mood disorders, sadness and depressive thoughts were present but minimal in severity. In contrast, inner tension and anxiety symptoms increased significantly over time only in these patients. Conclusions: Our results suggest that IFN-alfa-induced mood disorders are common and consist of an overlap between depressive and manic symptoms rather than a mere depression. The impact of such findings on therapeutic management should be investigated.

UR - http://www.scopus.com/inward/record.url?scp=15044362987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044362987&partnerID=8YFLogxK

U2 - 10.4088/JCP.v66n0814

DO - 10.4088/JCP.v66n0814

M3 - Article

C2 - 16086622

AN - SCOPUS:15044362987

VL - 66

SP - 1050

EP - 1057

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -